On March 16, 2021, pursuant to the Agreement and Plan of Merger, dated as of December 14, 2020, by and among Anchiano Therapeutics Ltd. (Anchiano), CMB Acquisition Ltd. (Merger Sub), and Chemomab Ltd. (Chemomab), Anchiano completed the previously announced merger transaction, pursuant to which Merger Sub merged with and into Chemomab, with Chemomab surviving such merger as a wholly owned subsidiary of Anchiano (the Merger). In connection with the Merger, on March 16, 2021, Anchiano changed its name to Chemomab Therapeutics Ltd. In accordance with the Merger Agreement, on March 16, 2021, upon the effective time of the Merger, Neil Cohen resigned as interim Chief Executive Officer of the company. In accordance with the Merger Agreement and an action of the Board, on March 16, 2021, the Board appointed Adi Mor as the company's Chief Executive Officer. Mor is a co-founder of Chemomab and has served as Chemomab's Chief Executive Officer, Chief Scientific Officer, member of Chemomab's board of directors since its formation in 2011.